中国国际金融股份有限公司 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海仁度 生物科技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行股票并在科创 板上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所 科创板股票上市规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》 等相关规定，负责仁度生物上市后的持续督导工作，并出具本持续督导半年度跟踪报 告，具体情况如下： 关于上海仁度生物科技股份有限公司 2024 年半年度持续督导跟踪报告 一、持续督导工作情况 | 序号 | 工作名称 | 实施情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 | 保荐机构已建立健全并有效执行了持 | | | 对具体的持续督导工作制定相应的工作计划。 | 续督导制度，并制定了相应的工作计 | | | | 划。 | | | 根据中国证券监督管理委员会（以下简称"中 | 保荐机构已与仁度生物签订保荐协 | | | 国证监会"）相关规定，在持续督导工作开始 | | | 2 | 前，与上市公司签署持续督导协议，明确双方 ...

北京市嘉源律师事务所 关于上海仁度生物科技股份有限公司 2024 年第二次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 H 关于上海仁度生物科技股份有限公司 2024年第二次临时股东大会的 2) E Um East In A YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海仁度生物科技股份有限公司 北京市嘉源律师事务所 本次股东大会的召集、召开程序 Í 嘉源(2024)-04-701 北京市嘉源律师事务所(以下简称"本所")接受上海仁度生物科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》")等现 行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以 及《上海仁度生物科技股份有限公司章程》(以下简称"《公司章程》")的有关规 定,指派本所律师对公司 2024年第二次临时股东大会(以下简称"本 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-049 上海仁度生物科技股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 38 | | --- | --- | | 普通股股东人数 | 38 | | 2、出席会议的股东所持有的表决权数量 | 19,864,762 | | 普通股股东所持有表决权数量 | 19,864,762 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.32 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 51.32 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由董事会召集，董事长居金良先生主持，会议采取现场投票和 网络投票相结 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-048 上海仁度生物科技股份有限公司 上海仁度生物科技股份有限公司 关于参加上海辖区上市公司 2024 年投资者 网上集体接待日暨中报业绩说明会的公告 董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步加强与投资者的互动交流，上海仁度生物科技股份有限公司（以下 简称"公司"）将参加由上海上市公司协会与深圳市全景网络有限公司联合举办的 "2024 年上海辖区上市公司投资者集体接待日暨中报业绩说明会"，现将相关事 项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net/html/143790.shtml），或关注微信公众号：全景财经，或下载全 景路演 APP 参与本次互动交流，活动直播时间为 2024 年 9 月 13 日（周五）14:00- 16:30。届时公司高管将在线就公司 2024 年度中报业绩、公司治理、发展战略、 经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资 ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-045 上海仁度生物科技股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 三、 审议通过《关于公司<2024 年半年度募集资金存放与实际使用情况 专项报告>的议案》 上海仁度生物科技股份有限公司（以下简称"公司"）第二届监事会第六次 会议于 2024 年 8 月 29 日在公司二楼会议室以现场结合通讯的表决方式召开。 会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。公司董事、 高级管理人员列席了监事会会议。本次监事会会议的召集、召开程序符合公司 章程和有关法律、法规的要求。经与会监事审议和表决，会议形成决议如下： 一、 审议通过《关于续聘会计师事务所的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 具体内容详见本公司 2024 年 8 月 30 日于上海证券交易所网站 （www.sse.com.cn）披露的《关于续聘 2024 年度会计师事务所的 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares, totaling approximately 3,870,857.20 yuan, which represents 89.38% of the net profit attributable to shareholders for the reporting period[5]. - The company does not have any special arrangements for corporate governance[7]. - The company has not implemented any other forms of profit distribution, such as capital reserve transfers or stock dividends, in this profit distribution plan[5]. - The company commits to a cash dividend policy, prioritizing cash dividends while ensuring long-term interests and sustainable development[88]. - The cash dividend ratio will be at least 80% for mature stages without major capital expenditures, 40% with major expenditures, and 20% for growth stages with major expenditures[88]. - The company will conduct annual dividends, with the possibility of mid-term dividends based on current profitability and cash flow[88]. Financial Performance - The company's operating revenue for the first half of 2024 was ¥86,680,181.82, representing an increase of 8.31% compared to ¥80,029,969.73 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was ¥4,330,811.17, a significant recovery from a loss of ¥10,192,633.27 in the previous year[17]. - The net cash flow from operating activities was ¥10,458,030.35, improving from a negative cash flow of ¥13,947,402.37 in the same period last year[17]. - The total assets at the end of the reporting period were ¥1,021,502,138.11, down 3.15% from ¥1,054,715,696.08 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased by 2.51% to ¥938,619,899.39 from ¥962,741,641.49 at the end of the previous year[17]. - The company achieved a net profit attributable to shareholders of 4.33 million yuan, an increase of 14.52 million yuan compared to the same period last year[18]. - Total operating revenue increased by 8.31% year-on-year, driven by strong sales growth in respiratory products[19]. - The company reported a total comprehensive income of RMB 9,970,669.76 for the first half of 2024, compared to a total comprehensive loss of RMB 5,869,665.10 in the previous year[136]. Research and Development - The company has invested 23.86% of its operating revenue in R&D, reflecting an increase of 0.62 percentage points year-on-year[18]. - The company holds a total of 63 patents, including 37 invention patents and 26 utility model patents[23]. - The company has obtained 20 CE certifications and 32 domestic medical device registration certificates, including 15 Class III medical device registration certificates[23]. - The company has developed a complete molecular diagnostic industry chain, including a patented RNA real-time fluorescence isothermal amplification detection technology platform[22]. - The company’s core self-produced enzyme industrial production technology has been established, enabling large-scale and high-purity production of raw material enzymes[33]. - The total R&D investment for the period was approximately ¥20.68 million, an increase of 11.19% compared to ¥18.60 million in the same period last year[38]. - The company is focusing on RNA constant temperature amplification technology, which enhances specificity and sensitivity in pathogen detection compared to DNA diagnostics[44]. Market Expansion and Strategy - The company is focusing on expanding its market presence and developing new technologies in RNA molecular diagnostics, particularly in the infection field[12]. - The company is actively pursuing new strategies for market expansion and product development to enhance its competitive position in the industry[12]. - The company achieved a significant milestone by obtaining 32 domestic medical device registration certificates, including 15 Class III and 17 Class I medical device certificates[37]. - The company is enhancing its organizational capabilities by optimizing personnel structure and attracting top talent to support international and domestic market expansion[51]. - The company focuses on expanding its market presence both domestically and internationally, enhancing its sales channels and academic promotion efforts[50]. Operational Risks and Governance - The company has outlined various operational risks and corresponding mitigation measures in the report[3]. - There are no non-operational fund occupations by controlling shareholders or related parties[6]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the semi-annual report[2]. - The company has committed to long-term effective measures to address related party transactions and competition issues[76]. - The company has a long-term effective commitment to dividend distribution[76]. Compliance and Regulatory Matters - The company is committed to maintaining compliance with regulatory standards, including obtaining EU CE certification for its products[12]. - The company guarantees the authenticity, accuracy, and completeness of the prospectus and all application documents, assuming legal responsibility for any false records or misleading statements[89]. - The company will comply with all relevant laws and regulations regarding shareholding and related party transactions[80]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[104]. - The company has not provided any guarantees that violate regulations during the reporting period[104]. Shareholder Commitments and Lock-up Periods - The controlling shareholder has pledged to minimize and regulate related party transactions to ensure fairness and independence[78]. - The company has established a lock-up period of 36 months for shares held by the controlling shareholder, with specific conditions for extension based on stock performance[79]. - If the company's stock price falls below the issue price for 20 consecutive trading days, the lock-up period will automatically extend by 6 months[79]. - Major shareholders and their affiliates commit to not transferring or managing shares held before the IPO for 36 months[84]. - The company will ensure that any share reductions by the controlling shareholder will not undermine its operational stability[80]. Financial Management and Cash Flow - The company's cash and cash equivalents decreased by 60.29% to 242,029,282.79 RMB due to increased investments in financial products[63]. - The total amount of financial assets at fair value increased by 788.33% to 446,032,291.66 RMB, primarily from purchasing more financial products[65]. - The company reported a cash outflow from financing activities of CNY 32,111,709.49, compared to CNY 6,360,045.48 in the first half of 2023, indicating a significant increase in cash outflow[139]. - The company received CNY 450,000,000.00 from investment recoveries, a substantial increase from CNY 168,388,888.89 in the same period last year, representing a growth of 167.5%[141]. - The company will strengthen internal controls and budget management to effectively manage operational risks and improve financial efficiency[98]. Legal and Regulatory Compliance - The company has not received any penalties or corrective actions related to violations of laws or regulations during the reporting period[105]. - The company and its controlling shareholders have not failed to fulfill obligations determined by effective legal documents during the reporting period[105]. - The company commits to taking measures if it fails to fulfill public commitments, including public apologies and compensation to investors for any losses incurred[103]. - The company will publicly explain any failure to adhere to these commitments and apologize to shareholders[84]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring a true and complete reflection of the company's financial status and operating results[157]. - The company follows a 12-month operating cycle, with its accounting year running from January 1 to December 31[158][159]. - The company’s financial statements are based on the assumption of going concern, indicating that it will continue its operations for the foreseeable future[155]. - The company recognizes its share of assets and liabilities in joint operations and accounts for income and expenses accordingly[166]. - The company applies the effective interest method for calculating interest on financial assets measured at amortized cost, with gains or losses recognized upon disposal[172].

证券代码：688193 证券简称：仁度生物 公告编号：2024-041 上海仁度生物科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购价格上限 | 53.31 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 1,291,428 股 | | 实际回购股数占总股本比例 | 3.2286% | | 实际回购金额 | 元 35,648,734.79 | | 实际回购价格区间 | 24.44 元/股~30.55 元/股 | 一、 回购审批情况和回购方案内容 公司于 2024 年 2 月 18 日召开第二届董事会第三次会 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/23 | | --- | --- | | 回购方案实施期限 | 第二届董事会第三次会议审议通过后 6 个月 | | 预计回购金额 | 元~50,000,000 元 25,000,000 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 股 1,291,428 | | 累计已回购股数占总股本比例 | 3.2286% | | 累计已回购金额 | 35,648,734.79 元 | | 实际回购价格区间 | 24.44 元/股~30.55 元/股 | 一、 回购股份的基本情况 证券代码：688193 证券简称：仁度生物 公告编号：2024-040 上海仁度生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号— ...

上海证券交易所 纪律处分决定书 〔2024〕137 号 关于对上海仁度生物科技股份有限公司及有关 责任人予以通报批评的决定 当事人： 蔡廷江，上海仁度生物科技股份有限公司时任财务总监兼董 -1- ──────────────────────── 上海仁度生物科技股份有限公司，A 股证券简称：仁度生物， A 股证券代码：688193； 居金良，上海仁度生物科技股份有限公司时任董事长； 于明辉，上海仁度生物科技股份有限公司时任总经理； 对于上述纪律处分事项，公司及有关责任人均提出异议称， 事会秘书。 一、上市公司及相关主体违规情况 经查明，2024 年 1 月 31 日，上海仁度生物科技股份有限公 司（以下简称公司）披露《2023 年年度业绩预告》，预计 2023 年年度实现归属于母公司所有者的净利润（以下简称归母净利润） 为 230 万元到 340 万元。2024 年 2 月 28 日，公司披露《2023 年 年度业绩快报公告》，预计 2023 年度实现营业利润为 7.51 万元， 利润总额为-60.46 万元，归母净利润为 318.22 万元，基本每股收 益为 0.08 元，加权平均净资产收益率为 0.33% ...

证券代码：688193 证券简称：仁度生物 公告编号：2024-039 上海仁度生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于以集中竞价交易方式回购公司股份比例 达到总股本 3%暨回购进展的公告 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，回购股份占上市公司总股本的比例每增加 1%的，应 当在事实发生之日起 3 个交易日内予以公告。现将公司回购股份进展情况公告如 下： 截至 2024 年 7 月 24 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 1,251,539 股，占公司总股本 40,000,000 股的比例为 3.1288%， 回购成交的最高价为 30.55 元/股，最低价为 24.44 元/股，已支付的资金总额为人 民币 34,656,300.25 元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 三、 其他事项 重要内容提示： | 回购 ...